CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
Home/Biomarker

FGFR2/3 mutation or fusion (urothelial)

Gene: FGFR3 · Type: mutation

Indications: Bladder cancer

SensitivityResistanceCIViC Context

FDA Sensitivity Assertions

DrugIndicationRecommendationFDA SourceLink
ErdafitinibBladder cancerINDICATED
FDA Label
Label